Overview

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
Details
Lead Sponsor:
Bayer
Treatments:
Radium Ra 223 dichloride
Succinylcholine